{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:06Z","timestamp":1786994406997,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.msard.2021.102935","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T02:06:48Z","timestamp":1617847608000},"page":"102935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"51","author":[{"given":"Anthony T","family":"Reder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-7270","authenticated-orcid":false,"given":"Nancy","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cortnee","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-3068","authenticated-orcid":false,"given":"Caroline","family":"Geremakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-5542","authenticated-orcid":false,"given":"Jason P","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Makin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7755-2781","authenticated-orcid":false,"given":"Megan C","family":"Vignos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102935_bib0001","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.msard.2021.102935_bib0002","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat. Med."},{"key":"10.1016\/j.msard.2021.102935_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","article-title":"Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database","volume":"6","author":"Boster","year":"2017","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2021.102935_bib0004","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s12325-020-01367-1","article-title":"Treatment patterns among patients with multiple sclerosis initiating second-line disease-modifying therapy","volume":"37","author":"Bowen","year":"2020","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.msard.2021.102935_bib0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.102935_bib0006","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","article-title":"Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates","volume":"55","author":"Caliceti","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.msard.2021.102935_bib0007","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1185\/03007995.2015.1014029","article-title":"Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis","volume":"31","author":"Capkun","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2021.102935_bib0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1352458519892555","article-title":"Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment","volume":"26","author":"Cohen","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102935_bib0009","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.msard.2018.02.021","article-title":"Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week","volume":"22","author":"Coyle","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Suppl 6","key":"10.1016\/j.msard.2021.102935_bib0010","doi-asserted-by":"crossref","first-page":"s53","DOI":"10.7861\/clinmedicine.16-6-s53","article-title":"Multiple sclerosis, a treatable disease","volume":"16","author":"Doshi","year":"2016","journal-title":"Clin. Med. (Lond)"},{"key":"10.1016\/j.msard.2021.102935_bib0011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/11596970-000000000-00000","article-title":"PEGylation of interferon-beta-1a: a promising strategy in multiple sclerosis","volume":"26","author":"Kieseier","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.102935_bib0012","first-page":"1385","article-title":"Quantifying differences in health care consumption for the management of multiple sclerosis within privately and publicly insured health care programs","volume":"22","author":"Livingston","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"1","key":"10.1016\/j.msard.2021.102935_bib0013","first-page":"S24","article-title":"Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis","volume":"19","author":"Menzin","year":"2013","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.msard.2021.102935_bib0014","unstructured":"National Multiple Sclerosis Society. Updated April 2020. Disease-modifying therapies for MS. http:\/\/www.nationalmssociety.org\/NationalMSSociety\/media\/MSNationalFiles\/Brochures\/Brochure-The-MS-Disease-Modifying-Medications.pdf. (accessed 23 July 2020)."},{"key":"10.1016\/j.msard.2021.102935_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101954","article-title":"Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide","volume":"40","author":"Newsome","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2021.102935_bib0016","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.msard.2021.102935_bib0017","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","article-title":"Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102935_bib0018","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by interferon \u03b2-1a in Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.102935_bib0019","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1185\/03007990903554257","article-title":"Persistence and adherence to disease modifying drugs among patients with multiple sclerosis","volume":"26","author":"Reynolds","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2021.102935_bib0020","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.neurol.2019.01.269","article-title":"Peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than glatiramer acetate once-daily in patients with RRMS: Propensity score matching of phase 3 data from ADVANCE and CONFIRM","volume":"175","author":"Scott","year":"2019","journal-title":"Revue Neurologique"},{"key":"10.1016\/j.msard.2021.102935_bib0021","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:15Z","timestamp":1761900975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":21,"alternative-id":["S2211034821002029"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102935","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102935"}}